United Kingdom

bit.bio secures $50M Series C to expand Human Cell Programming Platform
bit.bio, a Cambridge-based biotechnology company specialising in programmable human cells, has raised $50 million in a Series C financing round led by M&G Investments.

The best Articles in our Network